Eight years of treatment data for a single drug in a rare pediatric skeletal disorder is genuinely uncommon, and the 13.59 cm mean height difference vosoritide-treated children achieved versus untreated natural history cohorts after that duration is not a trivial number in achondroplasia — a condition where the entire therapeutic argument rests on whether proportional, sustained skeletal change is real or statistical noise.
The more consequential finding at PES, though, is not the height delta. It is the arm span-to-height ratio remaining stable across all age groups over the long-term extension studies. Achondroplasia produces disproportionate skeletal geometry, and critics of CNP-analog therapy have long questioned whether gains in standing height come at the cost of distorted segment ratios — essentially taller but no more proportional. The stability of that ratio undermines that critique directly. Separately, the DXA data from 119 children showing BMC increasing while BMD Z-scores held steady over six years addresses a different concern: that stimulating endochondral growth in already-dysregulated bone architecture could compromise mineral density. It does not appear to.
The hypochondroplasia data, while preliminary, carry real regulatory weight. The Phase 2 single-arm study from Children’s National Hospital showed a statistically significant improvement in total body minus head BMD of 0.03 g/cm² and BMC increase of 54.84 g at 12 months — both with p-values below 0.0001. Hypochondroplasia shares the FGFR3 gain-of-function mechanism with achondroplasia but presents more subtly, which has historically made diagnosis, enrollment, and endpoint selection harder. BioMarin‘s Phase 3 pivotal trial, CANOPY-HCH-3, has topline data expected before the end of June, with a regulatory submission planned for the second half of this year if results are positive. The biologics here are the same; the approval would extend the labeled population substantially.
The number that will define whether CANOPY-HCH-3 warrants a full label expansion is the annualized height velocity difference at 52 weeks — the same primary endpoint design that anchored the original achondroplasia approval. If it clears a clinically meaningful threshold in a condition with a smaller, harder-to-diagnose patient pool, BioMarin will have expanded vosoritide’s reach without inventing a new molecule.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
